scholarly journals Serum Ferritin as a Risk Factor for Myocardial Infarction

1970 ◽  
Vol 16 (1) ◽  
pp. 5-7
Author(s):  
MS Hafiz ◽  
MI Arslan ◽  
S Banarjee ◽  
M Obaidullah
Keyword(s):  
Risk Factors ◽  
Myocardial Infarction ◽  
Serum Ferritin ◽  
Ferritin Level ◽  
Premature Death ◽  
High Serum ◽  
Group A ◽  
The Mean ◽  
Group B ◽  
The Relationship

Myocardial Infarction (Ml) is the most common form of heart disease and the single mostimportant cause of premature death in the developed and developing world. Unfortunately theincidence of the condition is increasing rapidly in many developing countries like Bangladesh.Effort should therefore be taken to minimize the risk factors of Ml. There are several studieswhich evaluate the relation of serum ferritin with Ml in abroad. In Bangladesh, there is no suchstudy was carried out to evaluate the relationship between serum ferritin and Ml. So the presentwork has been designed to evaluate the association of serum ferritin with Ml.The present study was carried out in the Department of Biochemistry, BSMMU in collaborationwith Department of Cardiology, BSMMU and NICVD, Dhaka during the period of July 2001 toDecember 2002. A total of 50 subjects were selected, Group A ( 20 subjects of Ml) and Group B(30 subjects of Control). The mean level of serum ferritin in control subjects were 111.65 ±50.47 ng/ml and in test subjects were 258.44 ± 87.87 ng/ml. So the present study showed thatserum ferritin level is significantly higher in patients with Ml. From the present study, it isdifficult to draw any definite conclusion but suggested that high serum ferritin concentrationmay be a cause of the incidence of Ml.doi: 10.3329/taj.v16i1.3893TAJ June 2003; Vol.16(1): 5-7

scholarly journals Red meat and egg intake and serum ferritin concentrations in Colombian children: results of a population survey, ENSIN-2015

2020 ◽  
Vol 9 ◽  
Author(s):  
Oscar F. Herran ◽  
Jhael N. Bermúdez ◽  
María Del Pilar Zea
Keyword(s):  
Serum Ferritin ◽  
Serum Ferritin Level ◽  
Ferritin Level ◽  
Red Meat ◽  
Cross Sectional ◽  
Egg Consumption ◽  
Dietary Consumption ◽  
The Mean ◽  
The Relationship ◽  
Meat And Eggs

Abstract The present study aimed to (a) establish the frequency of consumption of red meat and eggs; (b) determine serum ferritin levels (μg/l); and (c) establish the relationship between serum ferritin and the consumption of red meat and eggs. In Colombia during 2014–2018, an analytical study was conducted in 13 243 Colombian children between the ages of 5 and 17 years, based on cross-sectional data compiled by ENSIN-2015 (Encuesta Nacional de la Situación Nutricional en Colombia-2015) on serum ferritin levels and dietary consumption based on a questionnaire of the frequency of consumption. Using simple and multiple linear regression, with the serum ferritin level as the dependent variable and the frequency of consumption as the main explanatory variable, the crude and adjusted partial regression coefficients (β) between serum ferritin levels and consumption were calculated. The frequency of habitual consumption of red meat was 0⋅49 (95 % CI 0⋅47, 0⋅51) times/d. The frequency of habitual egg consumption was 0⋅76 (95 % CI 0⋅74, 0⋅78) times per d. The mean serum ferritin level in men was 41⋅9 (95 % CI 40⋅6, 43⋅1) μg/l and in women, 35⋅7 (95 % CI 34⋅3, 37⋅7) μg/l (P < 0⋅0001). The adjusted β between the consumption of red meat and eggs and serum ferritin levels were β = 3⋅0 (95 % CI 1⋅2, 4⋅7) and β = 2⋅5 (95 % CI 1⋅0, 3⋅9) for red meat and eggs, respectively. In conclusion, red meat and eggs are determinants of serum ferritin levels in Colombia and, therefore, could be considered public policy options to reduce anaemia and Fe deficiency.

Cervical malalignment after laminoplasty: relationship to deep extensor musculature of the cervical spine and neurological outcome

2007 ◽  
Vol 7 (6) ◽  
pp. 610-614 ◽  
Author(s):  
Haku Iizuka ◽  
Takashi Nakajima ◽  
Yoichi Iizuka ◽  
Yasunori Sorimachi ◽  
Tsuyoshi Ara ◽  
...  
Keyword(s):  
Cervical Spine ◽  
Neurological Outcome ◽  
Neurological Recovery ◽  
Cervical Lordosis ◽  
Cervical Alignment ◽  
Female Patients ◽  
Group A ◽  
The Mean ◽  
Group B ◽  
The Relationship

Object The goal of this study was to investigate the relationship between preservation of the insertion of the deep extensor musculature of the cervical spine at C-2 and postoperative cervical alignment, especially differences between cases involving male and female patients, as well as the relationship between the loss of cervical lordosis and neurological outcome after laminoplasty. Methods The authors reviewed the records of 50 patients who underwent laminoplasty to elevate the C-3 lamina with repair of the deep extensor musculature (Group A) and 31 patients who underwent laminoplasty by C-3 dome laminotomy or laminectomy (Group B). They compared the degree of cervical lordosis after laminoplasty with preoperative measurements. Neurological function at last follow-up was also compared with preoperative assessments. Results In Group A, the mean values for pre- and postoperative cervical lordosis were 14.5 and 10.9°, respectively (p > 0.18). In female patients, however, the pre- and postoperative means were 14.4 and 3.7°, respectively (p < 0.004). In Group B, the overall means for pre- and postoperative cervical lordosis were 17.3 and 19.1°, respectively (p > 0.48); the corresponding means for female patients were 15.0 and 14.1° (p > 0.83). The mean percentages of neurological recovery were 54.1% in Group A and 54.8% in Group B. Conclusions Preservation of the insertion of the deep extensor musculature to the C-2 spinous process prevented significant changes in cervical alignment after laminoplasty, even among female patients. Neurological recovery was not affected by the loss of cervical lordosis.

Daily Oral Deferasirox versus Daily Oral Deferasirox + Intermittent Injectable Deferoxamine: Iron Chelators in Reducing Serum Ferritin Level in Thalassemia Major: a Randomized Trial

2020 ◽  
Author(s):  
Tanmay P Vagh ◽  
Mehul M Gosai ◽  
Jayendra Ratilal Gohil
Keyword(s):  
Serum Ferritin ◽  
Serum Ferritin Level ◽  
Ferritin Level ◽  
Genetic Disorder ◽  
Thalassemia Major ◽  
Iron Chelators ◽  
Intravenous Route ◽  
Blood Transfusions ◽  
Group A ◽  
Group B

Background: Thalassemia is a genetic disorder caused by an imbalance between α or β globin chain production resulting in an ineffective synthesis of hemoglobin chains. Treatment involves regular blood transfusions that cause iron build-up and tissue damage in organs causing, cardiomyopathy, diabetes, hyperthyroidism, interstitial lung fibrosis, cirrhosis, etc.Aims: To assess the efficacy of iron chelators: daily oral deferasirox vs combination of daily oral deferasirox + intermittent injectable deferoxamine in reducing serum ferritin level in thalassemia major patient. The main outcome was a decrease in serum ferritin after 1 year. Methods: They are randomly allocated into two groups. Both groups will take periodically blood transfusions but one group will receive oral deferasirox (group A) daily alone and group B will receive Deferasirox along with injectable deferoxamine by intravenous route only during periodic blood transfusions. In the B group along with it post-transfusion injectable deferoxamine will be given over four hours diluted in normal saline. Every 2 monthly serum ferritin level was done for 12 months.Results: Group A (n=30) with s ferritin mean± SD at base 7581.6±2389.7 and at 1 year 5288.5 ±2226.0, a decrease of 25.8%; and in Group B (n=30) with Mean± SD at base 9096.2± 3063.6 and 4698.4 ±2689.9 at 1 year, a decrease of 43.2% which is significant (p=&lt;0.001). Conclusion: A combination of daily oral deferasirox +intermittent injectable deferoxamine is a significantly better iron chelator, to decrease serum ferritin than oral deferasirox tablets in the subjects studied. No adverse events were noted.

Multidisciplinary Evaluation Improves Efficacy and Safety of Iron Chelation Therapy with Deferasirox in MDS Elderly Patients

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4558-4558
Author(s):  
Lisette Del Corso ◽  
Elisa Molinari ◽  
Andrea Bellodi ◽  
Riccardo Ghio ◽  
Andrea Bacigalupo ◽  
...  
Keyword(s):  
Serum Creatinine ◽  
Iron Overload ◽  
Serum Ferritin ◽  
Serum Ferritin Level ◽  
Chelation Therapy ◽  
Ferritin Level ◽  
Iron Chelation ◽  
Iron Chelation Therapy ◽  
Group A ◽  
Group B

Abstract BACKGROUND: Iron overload from chronic transfusion therapy can be extremely toxic and most patients (pts) do not receive adequate iron chelation therapy (ICT) despite evidence of transfusional iron overload (IOL). Deferasirox (DFX) is the principal option currently available for ICT in the management of IOL due to transfusion dependent anemia, such as in MDS pts. The most common adverse events (AEs) are gastrointestinal disorders, skin rash, elevations in liver enzymes levels and non-progressive transient increases in serum creatinine also in MDS pts, most of whom are elderly with significant comorbidities and side effects of other concomitant therapies. In order to achieve effective ICT with minimal toxicity in individual pts, regular monitoring to assess IOL and adverse effects of DFX treatment is essential. METHODS: The safety and efficacy of DFX were examined in a retrospective multicenter observational study of transfusion-dependent (TD) MDS pts with International Prognostic Scoring System (IPSS) low-or Int-1-risk. We included all pts treated with DFX up to 12 months, divided into two groups; the first one (group A) not under a multidisciplinary assessment, including pts not adequately treated, in terms of dosing and discontinuation of ICT and the second one (group B) with pts under multidisciplinary control. The DFX starting dosing was 10 mg/kg/die in all pts. The aim of our retrospective analysis was to assess the effectiveness of ICT in relation of dosing and right management of AEs. RESULT: We evaluated 45 MDS pts (12F/33M); 27 belonging to the group A and 18 to group B. The age was 74.2±8.8 and 77.3±4.8 respectively. The ECOG 0-1 was 85,1% in group A and 88,9% in group B. The transfusion episodes prior starting DFX were22.1±12.1 and 24.5±35.4 in the first and in the second group, respectively. The serum ferritin level at baseline was respectively 1285.1±489.6 ng/mL and 1452.6±748.1 ng/mL. The mean serum ferritin level increased from 1285.1+489.6 ng/mL to 1412.1+842.8 ng/mL in group A while decreased from 1452.6+748.1 ng/mL to 1166.1+ 723.4 ng/mL in group B. The rate of inadequate therapy, in terms of dosing and/or discontinuation ICT, was 85% in group A compared to 60% in group B (p= 0.086).The rate of severe SAE observed in all pts was 10%.The most common AEs were diarrhea, nausea, upper abdominal pain, serum creatinine increase. The positive hematological response rate was observed in 15% of all pts. CONCLUSIONS: The study showed that group B obtained advantage in terms of efficacy and toxicity. The difference between the two groups derived from the ability to manage comorbidities, concomitant therapies and AEs, in particular the rise in serum creatinine, the most common cause DFX discontinuation or dosing reduction. In this setting, the most important specialist was the nephrologist. In our multidisciplinary group experts in management of ICT were hematologist, internist, immune-hematologist and nephrologist. We shared how we monitored kidney function and managed a possible nephrotoxicity (table.2), in order to ensure DFX efficacy. Positive hematological responses were observed, and a subset of pts achieved transfusion independence. The timing of future multidisciplinary evaluation is set on 24 and 36 months, time in which we expect the best response to DFX therapy. Table 1. Ferritin trend group A (n27) group B (n18) Ferritin N mean±SD Median (range) N mean±SD Median (range) Baseline 27 1285.1±489.6 1134 (388-2099) 18 1452.6±748.1 1515 (160-3018) 3 months 22 1451.5±720.5 1247.5 (529-2791) 13 1312.7±909.8 1064 (521-3859) 6 months 23 1850.5±1079.1 1419 (374-4185) 11 1168.4±648.4 1300 (160-2409) 12 months 17 1412.1±842.8 1372 (111-3127) 9 1166.1±723.4 930 (277-2536) Table 2. Management of renal changes during therapy with DFX Creatinine and urine examination:1) in two successive determinations prior to initiation of therapy, then every month 2) in pts with other risk factors for kidney disease, every week for 1 month after start of DFX or dose increase and, subsequently, every month Changes in creatinine:1) increased by 33% in two successive determinations: reduce DFX dose of 5 mg/kg 2) progressive increase of creatinine: interrupt DFX and then re-challenge it at a lower dose with gradual increase if the clinical benefits outweigh the risks Disclosures No relevant conflicts of interest to declare.

The Effect of Combination Iron Chelating Agents on Reducing the Severity Grading of Heart and Liver Iron Overload in β-Thalassemia Patients

2019 ◽  
Author(s):  
Majid Ghanavat ◽  
Alireza Fazeli Varzaneh ◽  
Nahid Reisi
Keyword(s):  
Iron Overload ◽  
Serum Ferritin ◽  
Serum Ferritin Level ◽  
Ferritin Level ◽  
Iron Deposition ◽  
Liver Iron ◽  
Liver Iron Overload ◽  
Severity Grading ◽  
Group A ◽  
Group B

Background: Deferasirox (DFX), Deferoxamine (DFO), and Deferiprone (DFP) are iron chelators that can be used in thalassemic patients with iron overload. Materials and Methods: This clinical trial was performed on 108 thalassemic patients who were randomly divided into group A (n=54) and B (n=54). Group A received combination of DFX and DFP, and group B received DFO and DFP for six months. Serum ferritin level was measured at the beginning of the study, 3, and 6 months after the treatment; The heart and liver iron deposition rates were also measured at the beginning of the study, and 6 months after the treatment  in both groups and compared using Magnetic Resonance Imaging T2 plus (MRI T2*). Results: The mean age of patients in group A and B was 17.29±4.3 and 17.89±5.61 years old, respectively. Serum ferritin level significantly reduced after the treatment (Serum ferritin level at baseline, 3, and 6 months after the treatment in Group A: 2476.25±1289.32, 2089.62±1051.64 and 1290.22±724.78 ng/ml, respectively; in Group B: 2044.63±989.82, 1341.30±887.62 and 1229.41±701.22 ng/ml, respectively) (p<0.01, for both groups). MRI T2* heart and liver was also improved at the end of the study in both groups (p<0.01, for both groups). However, the combination of DFO/DFP significantly decreased severity grades of liver iron deposition in comparison to DFX/DFP regimen after six months (p<0.01). Conclusion: The results of the present study indicated that both combination therapies of DFO/DFP and DFX/DFP could improve heart and liver MRI T2*. However, DFO/DFP combination therapy was more effective in reducing the severity grades of liver iron deposition.     

scholarly journals Correlation between serum bilirubin and serum ferritin Level in thalassaemia patients

2013 ◽  
Vol 4 (2) ◽  
pp. 6-12 ◽  
Author(s):  
N Sultana ◽  
S Sadiya ◽  
MH Rahman
Keyword(s):  
Liver Function ◽  
Serum Ferritin ◽  
Serum Bilirubin ◽  
Common Finding ◽  
P Value ◽  
Thalassaemia Major ◽  
Minimum Level ◽  
Group A ◽  
The Mean ◽  
Group B

Thalassaemia is the most common hereditary disorder in the world including Bangladesh. Beta thalassaemia major and Hb-E thalassaemia both are common in our country. Iron overload causes most of the mortality and morbidity associate with thalassaemia. To assess the iron over load and liver function a cross sectional comparative study was carried out in the Department of Biochemistry, Dhaka Medical College, Dhaka in collaboration with Thalassaemia Center and Department of Pathology, Dhaka Shishu Hospital, Dhaka during the period of July 2006 to June 2007. The study was carried out with the patients who visited regularly in Dhaka Shishu Hospital Thalassaemia Centre (DSHTC) and had multiple transfusions (more than five) and age more than 2 years. To compare the state of liver function with normal healthy individuals' normal healthy persons were also included. Total 70 subjects were included in this study. The study subjects were distributed into two groups, the group - A (cases, n=40) and group - B (healthy controls, n=30). According to the major types of thalassaemia present in our country, group -A again divided into two, group - AI ?-thalassaemia major (n=12) and group - AII of Hemoglobin E ?-thalassaemia (n=28). The mean of serum Bilirubin in group - A and group - B were (2.04 ±0.70) mg/dl and (0.67±0.15) mg/dl respectively. Group - A had higher serum bilirubin than group -B in p value <0.001.The mean level of serum bilirubin in group - AI was (1.70±0.70)mg/dl and the mean of bilirubin in group AII was (2.18±0.66) mg/dl. Group -AI had lower serum bilirubin than group AII in p value <0.05. Pearson's correlation between serum bilirubin and serum ferritin had r value -0.26 was statistically not significant. Mean level of serum ferritin in the total was (2729.40 ± 1935.87) ng/ml, minimum level was 304 ng/ml and maximum was 7256ng/ml. Mean level of serum ferritin in the patients of ? - thalassaemia major was (4098.67 ± 1598.63) ng/ml, minimum level was 1212ng/ml and maximum was 7560ng/ml. Mean level of serum ferritin in the patients of HbE ? - thalassaemia was (2232.57± 1598.63) ng/ml, minimum level was 304ng/ml and maximum was 630ng/ml. Group AI had higher level of serum ferritin than group AII in p value <0.05.In conclusion, iron over load and jaundice are common finding of thalassaemia. In this present study serum ferritin and serum bilirubin parameter of iron over load and jaundice are correlated. But no statistical correlation was found between these two parameters. DOI: http://dx.doi.org/10.3329/bjmb.v4i2.13769 Bangladesh J Med Biochem 2011; 4(2): 6-12

scholarly journals Comparative Study of Risk Factors Between Lacunar and Non-lacunar Ischemic Strokes

2013 ◽  
Vol 28 (2) ◽  
pp. 88-95
Author(s):  
Dewan Md Elyas ◽  
Aminur Rahman ◽  
Quazi Deen Mohammad ◽  
Badrul Alam Mondol ◽  
Sakhawat Hossain ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Myocardial Infarction ◽  
Ischemic Stroke ◽  
Carotid Artery ◽  
Carotid Artery Stenosis ◽  
Artery Stenosis ◽  
Lacunar Stroke ◽  
Group A ◽  
Group B

Background: Stroke is a leading cause of mortality and morbidity in both developed as well as developing countries The risk factors in lacunar stroke differ in comparison to nonlacunar strokes. In this study risk factors of lacunar stroke in comparison to non-lacunar were evaluated. Objectives: The aim of the study was to compare the risk factors among lacunar stroke and non-lacunar stroke. Methodology: This comparative study conducted in the department of Medicine and Neurology, Dhaka Medical College Hospital, Dhaka from September 2010 to August 2011. MRI of brain was done in 151 patients above 18 years of age with ischemic stroke and Lacunar stroke was found in 31 patients and non-lacunar stroke was detected in 120 patients. Based on the inclusion and exclusion criteria from them 30 patients with lacunar stroke were selected as Group-A patients and equal number of non-lacunar stroke same ages as group B were compared of. The risk factors of stroke were defined as hypertension, diabetes mellitus, hypercholesterolemia, smoking, history of transient ischemic attack, myocardial infarction, atrial fibrillation and carotid artery stenosis. Results: Out of 151 patients with ischemic stroke non-lacunar stroke was predominant, which was 79.47% and lacunar stroke was 20.52%. The mean age was found 60.9±10.2 years in Group A and 56.2±11.8 years in Group B, which was almost similar between two groups (p>0.05). Male were predominant, which was 63.33% and 76.67% in lacunar and non-lacunar stroke respectively. Male and female ratio was 2.3:1. Regarding the risk factors hypertension was observed most common risk factor among the patients having lacunar and non-lacunar strokes. Hypertension and diabetes mellitus were common in lacunar stroke and myocardial infarction, carotid artery stenosis and hypercholesterolemia were common in non-lacunar stroke which were statistically significant (p<0.05) between the both groups. However, the percentage of smoking, previous TIA and atrial fibrillation were not significantly (p>0.05) different between lacunar and non-lacunar stroke. Conclusion: Hypertension and diabetes mellitus were common in lacunar stroke, and myocardial infarction, whereas carotid artery stenosis and hypercholesterolemia were common in non-lacunar stroke and the both groups were statistically significant (p<0.05) . So modification of risk factors may reduce the incidence of ischemic stroke. DOI: http://dx.doi.org/10.3329/bjn.v28i2.17176 Bangladesh Journal of Neuroscience 2012; Vol. 28 (2): 88-95

scholarly journals Efficacy and adverse events related to the initial dose of methimazole in children and adolescents with Graves’ disease

2021 ◽  
Vol 26 (3) ◽  
pp. 199-204
Author(s):  
Hyun Gyung Lee ◽  
Eun Mi Yang ◽  
Chan Jong Kim
Keyword(s):  
Adverse Events ◽  
Children And Adolescents ◽  
Liver Dysfunction ◽  
Initial Dose ◽  
Graves Disease ◽  
Group A ◽  
The Mean ◽  
Group B ◽  
The Relationship ◽  
Mean Time

Purpose: The first-line antithyroid drug for children and adolescents with Graves’ disease (GD) is methimazole (MMI). This study evaluated the relationship between the initial MMI dose and the clinical course of GD after treatment.Methods: We studied the efficacy of the initial MMI dose and the relationship between the initial MMI dose and adverse events (AEs). We retrospectively enrolled 22 males and 77 females and divided those subjects into 3 groups according to the initial dose of MMI: <0.4 mg/kg/day (group A; n=32); 0.4–0.7 mg/kg/day (group B; n=39); and >0.7 mg/kg/day (group C; n=28).Results: The mean time to the normalization of free thyroxine (fT4) levels upon initial treatment was 5.64, 8.61, and 7.98 weeks in groups A, B, and C, respectively (P=0.116). The incidence of liver dysfunction, neutropenia, and skin rash was 12.5%, 20.5%, and 42.9% in groups A, B, and C, respectively (P=0.018). Neutropenia, as a severe AE, was absent in group A, but its prevalence was 7.7% in group B and 21.4% in group C (P=0.015). When comparing only groups B and C, the incidences of liver dysfunction and neutropenia were higher in group C (P=0.04 and P=0.021, respectively).Conclusion: The mean time to the normalization of fT4 levels did not differ among the 3 groups, but the incidence of AEs was higher in the groups that received high MMI doses. High doses of MMI (>0.7 mg/kg/day) should be reconsidered as an initial treatment for children and adolescents with GD.

scholarly journals Adverse in-hospital prognosis in patients with non-ST-segment elevation myocardial infarction with right bundle branch block – red flag ECG and sicker patients

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
M Saraiva ◽  
A R Moura ◽  
N Craveiro ◽  
B Castilho ◽  
K Domingues ◽  
...  
Keyword(s):  
Risk Factors ◽  
Myocardial Infarction ◽  
Cardiovascular Risk ◽  
Independent Predictor ◽  
Coronary Anatomy ◽  
Bundle Branch Block ◽  
St Segment Elevation ◽  
St Segment ◽  
Group A ◽  
Group B

Abstract Introduction Recent recommendations regarding myocardial infarction (MI) underline the adverse prognosis associated with right bundle branch block (RBBB), suggesting that, in some cases of non-ST-segment elevation MI (NSTEMI) with RBBB a primary percutaneous coronary intervention (PCI) strategy should be considered. However, it is unclear if this is due to a more difficult and late diagnosis or to the clinical severity inherent to these patients (pts). Purposes To characterize the NSTEMI with RBBB population and find predictors of worse prognosis. Methods Retrospective analysis of pts included in the Portuguese Registry of Acute Coronary Syndromes with NSTEMI, comparing pts with RBBB (group A) vs without RBBB (group B), regarding clinical and demographic variables, diagnostic and therapeutic approaches. Primary endpoint was heart failure, electrical and mechanical complications and death in the in-hospital period. Results We included 9375 pts, 686 in group A and 8689 in group B. Pts in group A were more likely to be male (p&lt;0.001) and over 75 years old (p&lt;0.001). Also, they were more prone to have cardiovascular risk factors (hypertension - p&lt;0.001, diabetes – p&lt;0.001) and history of coronary artery disease (stable angina p=0.007, previous MI p=0.002 and revascularization, either PCI – p=0.016 or surgery – p&lt;0.001), stroke (p&lt;0.001), chronic kidney disease (p&lt;0.001) and cancer (p=0.025), comparing to pts in group B. There were no differences between time from onset of symptoms and first medical contact or hospital admission between groups. Upon admission, these pts presented more frequently with hypotension (p=0.026), Killip class&gt;II (p&lt;0.001) and atrial fibrillation (p&lt;0.001) than pts in group B. There were statiscally significant differences between groups, regarding the use of inotropes (p&lt;0.001), non-invasive (p=0.008) and invasive ventilation (p=0.018) and temporary pacing (p=0.001), all of them higher in group A. Pts with RBBB were less likely to undergo coronary angiography (CA) (p&lt;0.001). However, among those who did, there were no differences in CA timing (p=0.091), but pts from group A had more frequently multivessel disease (p=0.044) and no revascularization was undertaken (p=0.012). About 16.64% of all pts reached the endpoint, but unfavourable in-hospital outcome was significantly more common in group A (p&lt;0.001). RBBB remained an independent predictor of the endpoint (p=0.032) in a multivariate regression analysis, controlled for other variables (namely gender, age, cardiovascular risk factors, previous evidence of cardiovascular disease, and clinical and coronary anatomy data) – AUC of 0.833. Conclusion Although pts with NSTEMI and RBBB have a poorer in-hospital prognosis, partly due to their bigger clinical complexity (older age, multiple comorbidities and complex coronary anatomy), RBBB itself still remains an independent predictor of worse outcome. FUNDunding Acknowledgement Type of funding sources: None.

Sign in / Sign up

Export Citation Format

Share Document